NLARx Newsletter Header
NLARx News
Special Holiday Edition - December 21, 2009
Next issue: January 13, 2010
In This Issue
Save the date!
NLARx News
In the States
Outrage of the Week
Health Reform
Prices & Access
Fraud & Abuse
Conflicts of Interest
Patents & Generics
Reimportation
Advertising & Marketing
Pharma Watch
PBM Watch
Medicare & Medicaid
Safety & Clinical Trials
Quick Links
Join Our Mailing List
Save the Date
NLARx Winter Meeting, Washington DC, February 26
NLARx News
NLARx Statement in Support of Julie Brill's Nomination to the FTC More
Obama FTC Nominee Brill Faced Drug-Benefit Managers More
In the States
MAINE: Lawmakers Redraw Bill Aimed at Online Protection of Minors More
MARYLAND: Higher Prescription Drug Spending Concerns Marylanders More
WISCONSIN: State Cuts $600 Million From Medicaid Budget, Still Faces Deficit More
FLORIDA: Feds Probe High Prescribing Doctors More
TEXAS: State Pension Fund Awards CVS Caremark $1B 2-Year Contract More
Outrages of the Week
Menopause, as Brought To You by Big Pharma More
Poor Children Likelier to Get Antipsychotics More
One Psychiatrist, 21 Months, 96,685 Prescriptions More
Pharmaceuticals and Health Reform
Senate Managers Amendment #3276 - Moves Healthcare Reform Forward Download Amendment
Complete Senate Reform Bill: Patient Protection and Affordable Care Act Download Legislation
Importing Drugs Is Out; Mining Docs' Prescriptions Is (Still) In More
PhRMA's $80 Billion Deal Helps Nix Reimportation More
Pharma May Pay $20 Billion More For Health Bill More
Pharma Deal With White House Delays Health Reform More
Senate Amendment Would Block Data Mining More
Drug Importation Takes Center Stage On Senate Floor More
Going to Bat for Tax-Free Botox More
Drugmakers Attract Scrutiny But May Benefit From Overhaul More
Prices and Access to Health Care
Drug Costs Doubled In One Decade More
For Adults, Drug Costs Doubled From 1996 to 2006 More
Pharma Comes Under Fire for Jump in Rx Prices More
How Do International Drug Prices Stack Up? More
Pharma Faces More Scrutiny on Drug Prices More
Fraud and Abuse
Pharmacy Owner Sentenced to 12 Years Jail Term for Internet Drug Fraud More
Healthcare Fraud Still Main Focus of False Claims Act More
Schering-Plough Pays $21 Million To Settle Fraud Claim More
Conflicts of Interest
HHS Inspector Proposes CME, Group Looks at Link Between Pharma, Senators More
Merck Lands Med School Dean; an Acting CFO at Bristol-Myers More
Pharma, Conflicts Of Interest And Fingerpointers More
GSK Makes Physician Payments Public More
Which Doctors Are Getting Paid By Glaxo, Lilly and Merck? More
Northwestern Med School Discloses Industry Ties More
Patents and Generics
Are You Confident in Generic Drugs? More
USPTO Upholds Singulair Patent More
UNITAID Approves A Patent Pool For AIDS Medicines More
Can New Zyprexa Fight Generic Competition? More
Extended-Release Antipsychotics, for Extended Patent Protection More
Dr. Reddy's Challenges Pfizer's Patent for Top-Selling Lipitor More
AZ, Lilly, BMS Face Steepest Patent Cliff More
EU Raids Drugmakers Over Generic Deals More
Reimportation
Administration: Obama to Push for Allowing Drug Re-Importation More
White House Promises To Allow Imports In Bill Separate From Healthcare Reform More
Amendment To Allow Drug Importation Fails In Senate More
PhRMA Statement on Prescription Drug Importation More
Drug Importation, Senate Votes And Money More
Prescription Drug Import Amendment Divides Senate Democrats More
Senate Rejects Plan To Reimport Drugs More
Advertising and Marketing
Zetia's Miraculous Popularity More
A Prescription for Snooping More
Should Docs' Prescribing Habits Be for Sale? More
A Certification For Sales Reps Is On Its Way More
Pfizer Marketing Whistleblower Tops Business Ethics List More
The Decline and Fall of the Pharma Rep More
Death of a Salesman: Drugmakers Recast the Role of Reps More
Pfizer Adds New Type of Tablet to Sales Calls More
Pharma Watch
Sanofi to Buy U.S. Group Chattem for $1.9 Billion More
Merck and J&J Land Deals; Biogen Idec, Not So Much More
NAMI Runs A Survey On Pharma Funding More
The Start of a Comeback for Pfizer's Dividend? More
More Companies Are Disclosing Their Political Activity More
Eli Lilly Isn't Planning to Buy Its Way Around the Patent Cliff More
Pfizer, Merck, Abbott and Lilly Deals in SEC Insider Trading Probe More
SEC Probes Four Pharmas for Insider Trading More
China's Drug Industry On the Rise, Analysts Say More
GSK Stakes Its Emerging Markets Claim More
PBM Watch
WellPoint Stock Surges As Public Plan Struggles More
CVS Gets $1 Billion Benefits Contract in Texas More
CVS Faces Scrutiny in $1 Billion Texas Contract Bid More
Medicare and Medicaid
New Data Spotlights Premiums, Benefit Design and Cost Sharing For 2010 Part D Medicare Drug Plans More
26 Arrested in Three States in Medicare Fraud Schemes More
Democrats Vow to Close Medicare 'Doughnut Hole' More
Senate Moves to Fix Doughnut Hole in Medicare Part D More
Recession Doesn't Keep Some States From Expanding Health Coverage More
Safety and Clinical Trials
GAO: Post-Vioxx, Still No Safety Changes at FDA More
FDA Has Failed To Make Safety Changes: GAO More
Infants' Swine Flu Vaccine Is Recalled as Less Potent More
The Paxil Legal Bill: Glaxo Spends $1 Billion So Far More
Drug Can Stop Strokes, But Most Patients Don't Get It More
Pfizer Wins Dismissal Of 23 Prempro Lawsuits More
Merck Loses Effort to Dismiss 24 Fosamax Cases More
Antidepressants And Stroke Risk In Older Women More
IOM Issues Review Of National Vaccine Strategy More
Amgen's Next Big Thing Gets a Thumbs Up in Europe More